Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 2/20 | 0.40 |
| ▸ | EDNRB | P24530 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | C1R | P00736 | 1/20 | 0.34 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.33 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.33 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.33 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29799735 | 1.00 | EDNRA (0.40) | EDNRAEDNRBL3MBTL1KMT2ATDP1 | |
| SCHEMBL30171015 | 0.90 | EDNRA (0.37) | EDNRAEDNRBL3MBTL1KMT2ATDP1 | |
| SCHEMBL6640127 | 0.90 | EDNRA (0.37) | EDNRAEDNRBL3MBTL1KMT2ATDP1 | |
| SCHEMBL25289959 | 0.88 | EDNRA (0.39) | EDNRAEDNRBL3MBTL1KMT2ATDP1 | |
| SCHEMBL26688761 | 0.86 | EDNRA (0.40) | EDNRAEDNRBL3MBTL1KMT2ATDP1 | |
| SCHEMBL5525533 | 0.85 | EDNRA (0.37) | EDNRAEDNRBL3MBTL1KMT2ATDP1 | |
| SCHEMBL5525532 | 0.85 | EDNRA (0.37) | EDNRAEDNRBL3MBTL1KMT2ATDP1 | |
| SCHEMBL30296075 | 0.85 | EDNRA (0.37) | EDNRAEDNRBKMT2ATDP1GAA | |
| SCHEMBL27419866 | 0.85 | EDNRA (0.37) | EDNRAEDNRBKMT2ATDP1GAA | |
| SCHEMBL25084130 | 0.85 | TSHR (0.31) | EDNRAGAAALDH1A1TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025094214-A1 | Process for the preparation of 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(ethoxymethyl)phenyl]-N-(4,5-dimethyl-1,2-oxazol-3-yl) benzenesulfonamide and its intermediates thereof | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2025-05-08 | — | — | WO | disclosed |
| US-20250051315-A1 | COMPOUND, ANGIOTENSIN II TYPE 1 RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION | ALCHEMEDICINE, INC. (JP) | 2025-02-13 | — | — | US | disclosed |
| EP-4458826-A1 | COMPOUND, ANGIOTENSIN II TYPE 1 RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION | Alchemedicine, Inc. (JP) | 2024-11-06 | — | — | EP | disclosed |
| EP-4393920-A1 | AROMATIC RING-CONTAINING BIOLOGICAL ANTAGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
| CN-118284605-A | Compounds, angiotensin II type 1 receptor antagonists and pharmaceutical compositions | 亚克医药株式会社 | 2024-07-02 | — | — | CN | disclosed |
| CN-117836294-A | Biological antagonist containing aromatic ring, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-04-05 | — | — | CN | disclosed |
| WO-2023224963-A1 | DUAL-ACTING ANGIOTENSIN AND ENDOTHELIN RECEPTOR ANTAGONISTS | ARIA PHARMACEUTICALS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023224963-A1 | DUAL-ACTING ANGIOTENSIN AND ENDOTHELIN RECEPTOR ANTAGONISTS | ARIA PHARMACEUTICALS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| CN-117085013-A | Biphenyl sulfonamide compounds useful for treating kidney diseases or conditions | 特拉维尔治疗公司 | 2023-11-21 | — | — | CN | disclosed |
| CN-117017985-A | Biphenyl sulfonamide compounds useful for treating kidney diseases or conditions | 特拉维尔治疗公司 | 2023-11-10 | — | — | CN | disclosed |
| WO-2023127853-A1 | COMPOUND, ANGIOTENSIN II TYPE 1 RECEPTOR ANTAGONIST, AND PHARMACEUTICAL COMPOSITION | 株式会社アークメディスン | 2023-07-06 | — | — | WO | disclosed |
| WO-2023025277-A1 | AROMATIC RING-CONTAINING BIOLOGICAL ANTAGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2023-03-02 | — | — | WO | disclosed |
| WO-2023025277-A1 | AROMATIC RING-CONTAINING BIOLOGICAL ANTAGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2023-03-02 | — | — | WO | disclosed |
| CN-114788823-A | Biphenyl sulfonamide compounds for use in the treatment of renal diseases or disorders | 特拉维尔治疗公司 | 2022-07-26 | — | — | CN | disclosed |
| WO-2018071784-A1 | BIPHENYL SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF KIDNEY DISEASES OR DISORDERS | Retrophin, Inc. (US) | 2018-04-19 | — | — | WO | disclosed |
| US-20040059123-A1 | Such as N-(methoxymethyl)-N-(4,5-dimethyl-3-isoxazolyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzenesulfanamide; endothelin antagonists for treatment of hypertension; high melting | POLNIASZEK RICHARD P (US) | 2004-03-25 | — | — | US | disclosed |
| US-6639082-B2 | Cycloboronate intermediates; endothelin antagonists useful, inter alia, for the treatment of hypertension. | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-28 | — | — | US | disclosed |
| EP-1328523-A2 | METHODS FOR THE PREPARATION OF BIPHENYL ISOXAZOLE SULFONAMIDES | Bristol-Myers Squibb Company (US) | 2003-07-23 | — | — | EP | disclosed |
| US-20020132838-A1 | Methods for the preparation of biphenyl isoxazole sulfonamides | BRISTOL-MYERS SQUIBB COMPANY | 2002-09-19 | — | — | US | disclosed |
| WO-2002032884-A2 | METHODS FOR THE PREPARATION OF BIPHENYL ISOXAZOLE SULFONAMIDES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132838-A1 | Methods for the preparation of biphenyl isoxazole sulfonamides | REN, STS, CYP4X1 | EDNRA 11/4885EDNRB 12/4885L3MBTL1 4687/4885 |
| US-20250051315-A1 | COMPOUND, ANGIOTENSIN II TYPE 1 RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION | AGTR1, AGTR2, ADRB1 | EDNRA 154/4885EDNRB 216/4885L3MBTL1 4528/4885 |
| US-20040059123-A1 | Such as N-(methoxymethyl)-N-(4,5-dimethyl-3-isoxazolyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzenesulfanamide; endothelin antagonists for treatment of hypertension; high melting | EDNRA, EDNRB, ECE1 | EDNRA 1/4885EDNRB 2/4885L3MBTL1 3666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.